[Efficacy and safety evaluation of gemcitabine combined with oxaliplatin in lymphoma patients after failure of multiple chemotherapy regimens].

Jian-liang Yang, Yuankai Shi, Xiaohui He, Shengyu Zhou, Mei Dong, Peng Liu, Changgong Zhang, Yan Qin, Sheng Yang, Lin GuiPubMed 2014

Abstract

GEMOX regimen can get a better response rate in lymphoma patients after failure of multiple chemotherapy regimens, and with a good tolerance and acceptable safety. Some patients can get long-term survival. Patients sensitive to the last chemotherapy are more likely to benefit from GEMOX regimen.
BibTeX
@inproceedings{yang2014efficacy,
  author = {Jian-liang Yang and Yuankai Shi and Xiaohui He and Shengyu Zhou and Mei Dong and Peng Liu and Changgong Zhang and Yan Qin and Sheng Yang and Lin Gui},
  title = {{[Efficacy and safety evaluation of gemcitabine combined with oxaliplatin in lymphoma patients after failure of multiple chemotherapy regimens].}},
  booktitle = {PubMed},
  year = {2014},
}

Loading related content...

Figure